Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

69.92
-0.0800-0.11%
Post-market: 69.920.00000.00%19:30 EDT
Volume:255.90K
Turnover:17.93M
Market Cap:3.60B
PE:6.30
High:70.64
Open:70.46
Low:69.84
Close:70.00
52wk High:74.59
52wk Low:56.44
Shares:51.55M
Float Shares:51.55M
Volume Ratio:0.70
T/O Rate:0.50%
Dividend:0.81
Dividend Rate:1.16%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.29
PE(LYR):22.86

Loading ...

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

2 Reasons Cooper Companies Stock is by Far the Worst in the S&P 500 Today

Dow Jones
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Producer Price Inflation Data Release

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10